Quality-of-life utilities
| . | Median . | Range . |
|---|---|---|
| Allo-HCT in CR1 | ||
| No relapse without GVHD | 0.90 | 0.60-1.00 |
| No relapse with GVHD | 0.60 | 0.40-0.80 |
| Relapse | 0.30 | 0.20-0.70 |
| Chemotherapy in CR1 | ||
| No relapse | 0.90 | 0.80-1.00 |
| Relapse | 0.50 | 0.20-0.80 |
| Second remission | 0.80 | 0.40-0.95 |
| After salvage allo-HCT | 0.66 | 0.10-1.00 |
| . | Median . | Range . |
|---|---|---|
| Allo-HCT in CR1 | ||
| No relapse without GVHD | 0.90 | 0.60-1.00 |
| No relapse with GVHD | 0.60 | 0.40-0.80 |
| Relapse | 0.30 | 0.20-0.70 |
| Chemotherapy in CR1 | ||
| No relapse | 0.90 | 0.80-1.00 |
| Relapse | 0.50 | 0.20-0.80 |
| Second remission | 0.80 | 0.40-0.95 |
| After salvage allo-HCT | 0.66 | 0.10-1.00 |
Allo-HCT indicates allogeneic hematopoietic cell transplantation; CR1, first complete remission; and GVHD, graft-versus-host disease.